lapatinib has been researched along with vadimezan in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 272 | 16 | 101 |
| Protein | Taxonomy | lapatinib (IC50) | vadimezan (IC50) |
|---|---|---|---|
| Stimulator of interferon genes protein | Mus musculus (house mouse) | 1.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ye, G; Zhang, C; Zhang, J | 1 |
1 other study(ies) available for lapatinib and vadimezan
| Article | Year |
|---|---|
Stimulator of interferon response cGAMP interactor overcomes ERBB2-mediated apatinib resistance in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Head and Neck Neoplasms; Humans; Interferons; Lapatinib; Male; Membrane Proteins; Mice, Inbred BALB C; Nucleotides, Cyclic; Pyridines; Receptor, ErbB-2; Squamous Cell Carcinoma of Head and Neck; Vascular Endothelial Growth Factor Receptor-2; Xanthones; Xenograft Model Antitumor Assays | 2021 |